U.S. Markets open in 7 hrs 14 mins

  • S&P Futures

    3,902.00
    +4.25 (+0.11%)
     

  • Dow Futures

    31,241.00
    +39.00 (+0.12%)
     

  • Nasdaq Futures

    11,838.00
    -40.25 (-0.34%)
     

  • Russell 2000 Futures

    1,771.50
    -3.40 (-0.19%)
     

  • Crude Oil

    110.35
    +0.46 (+0.42%)
     

  • Gold

    1,845.10
    +3.90 (+0.21%)
     

  • Silver

    21.87
    -0.03 (-0.13%)
     

  • EUR/USD

    1.0562
    -0.0026 (-0.2429%)
     

  • 10-Yr Bond

    2.7870
    -0.0680 (-2.38%)
     

  • Vix

    29.43
    +0.08 (+0.27%)
     

  • GBP/USD

    1.2495
    +0.0020 (+0.1587%)
     

  • USD/JPY

    127.8500
    +0.0560 (+0.0438%)
     

  • BTC-USD

    30,345.28
    +951.74 (+3.24%)
     

  • CMC Crypto 200

    650.34
    -23.03 (-3.42%)
     

  • FTSE 100

    7,389.98
    +87.24 (+1.19%)
     

  • Nikkei 225

    26,739.03
    +336.19 (+1.27%)
     

Greenwich LifeSciences Reveals 5-Year Data for GP2 Immunotherapy In Breast Cancer Settings

  • Oops!
    Something went wrong.
    Please try again later.
Vandana Singh
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • GLSI

Greenwich LifeSciences Inc (NASDAQ: GLSI) has published new GP2 Phase 2b trial data. The trial enrolled HER2 positive patients, who received a standard course of trastuzumab after surgery, and HER2 low patients, who did not receive trastuzumab after surgery.

  • 22.8% or 33 of the 145 patients reacted to GP2 at baseline with a positive immune response.

  • Of the 33 patients who did have a positive baseline DTH immune response to GP2, eight patients recurred, a recurrence rate of 24.2%, with a median time to recurrence of 99 days (0.27 years).

  • Of the 112 patients who did not have a positive DTH baseline immune response to GP2, 14 patients recurred a recurrence rate of 12.5%, with a median time to recurrence of 438 days (1.2 years).

  • If the patient completed the Primary Immunization Serie, the 5-year disease-free survival rate in the 46 HER2 3+ patients treated with GLSI-100 was 100% versus 89.4% in the 50 placebo patients treated with GM-CSF.

  • GLSI-100 was found to be well tolerated with no SAEs deemed related to study medication and elicited a potent immune response.

  • Injection site reactions were common, occurring in almost 100% of patients treated with either GLSI-100 or GM-CSF alone.

  • Price Action: GLSI shares are down 8.52% at $31.69 during the market session on the last check Thursday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Recommended Stories

  • Which beaten down stocks should I buy for the juiciest upside? Here are 3 high-growth tech ideas hitting fresh 52-week lows

    This trio might be ice cold. But Wall Street says they now have up to 86% upside.

  • Stock Selloff to Intensify as Fresh 10% Plunge Looms, Survey Finds

    (Bloomberg) -- Get ready for a fresh slump in the world’s most-watched stock index, as economic growth fears spiral and the Federal Reserve embarks on its biggest policy-tightening campaign in decades.Most Read from BloombergWalmart’s Troubles Should Have Everyone on High AlertA $5 Trillion ‘Wealth Shock’ Is Cracking Americans’ Nest EggsBroadcom in Talks to Acquire Cloud Company VMwareHow an Energy Expert Triggered Vladimir Putin With One WordStocks Steady as China Sours Mood; Dollar Dips: Marke

  • Suze Orman says you can avoid 5 common mistakes people make in a stock market crisis

    If a major recession is coming, the financial guru recommends some fast, concrete moves to protect your money.

  • Goldman Sachs: 4 'buy' rated stocks for the rest of 2022 with up to 101% upside

    The first half of 2022 has been rocky. But Goldman likes this group to bounce back.

  • Broadcom in Talks to Acquire Cloud Company VMware

    (Bloomberg) -- Broadcom Inc. is in talks to acquire cloud-computing company VMware Inc., according to people familiar with the matter, setting up a blockbuster tech deal that would vault the chipmaker into a highly specialized area of software. Most Read from BloombergWalmart’s Troubles Should Have Everyone on High AlertA $5 Trillion ‘Wealth Shock’ Is Cracking Americans’ Nest EggsBroadcom in Talks to Acquire Cloud Company VMwareHow an Energy Expert Triggered Vladimir Putin With One WordStocks St

  • A Harvard economist says the economy looks bad right now, but a recession isn’t a sure thing. It all depends on these 2 factors

    Fears of a recession are mounting, but this economist is unwilling to get drawn into the drama just yet

  • Deere's Profits Double. Investors Sell.

    On Friday morning, agricultural equipment giant Deere & Company (NYSE: DE) announced that it just grew its profits about twice as fast as it grew its sales. Reporting its financial results for its fiscal second quarter 2022 Friday, Deere said its net sales and revenue came in at $13.4 billion, up 11% year-over-year. In just the first two hours of trading Friday, Deere stock fell 11.5%.

  • Stock Market Is Near Capitulation As Market Rotation Out From This Sector

    Market rotation out from this defensive sector could signal the start of stock market capitulation based on the analogue comparison of the global financial crisis in 2008.

  • How to Make Money (or Even Get Rich) During a Stock Market Crash

    Nobody knows when a stock (or the stock market) has hit bottom. People can speculate -- and every analyst hoping for a little bit of television fame most certainly will -- but no person, no matter how many past predictions they claim to have gotten right knows when a stock or the market has fallen as low as it will go. Down markets, bear markets, market crashes -- whatever you want to call them follow no rules.

  • Broadcom in Advanced Talks to Buy VMware

    The tech companies are discussing a cash-and-stock deal that could come soon, setting the stage for what would be one of the year’s biggest deals.

  • Should You Buy Amazon Now or Wait Until After the Stock Split?

    Since these are the two businesses Amazon dominates, it sold off hard. The hints of last week's retail destruction were actually forecast by Amazon back in its April first-quarter earnings report. Operating income actually declined from $8.7 billion a year ago to just $3.7 billion.

  • U.S. Stocks Poised to Open Higher on Monday

    On Wednesday, the Federal Open Market Committee publishes the minutes from its May monetary-policy meeting, and on Friday, the Bureau of Economic Analysis reports the personal consumption expenditure price index for April.

  • China Ride-Hailing Giant Didi Investors to Vote on N.Y. Delisting

    Chinese ride-hailing giant Didi Global Inc. is widely expected to secure a blessing from its shareholders on Monday to delist in New York. Peter Elstrom reports on "Bloomberg Markets: China Open."

  • Market Volatility Is Creating Opportunities; Here Are 2 ‘Strong Buy’ Stocks to Watch

    With the world gripped by an increasingly long list of negative macro trends, the market has followed suit, showing a decidedly bearish slant in 2022. Investors have been trying to make sense of the chaos. At times it has appeared as if no stocks can withstand the gloomy macro developments. This kind of market behavior, however, creates opportunities for investors willing to seize a bit of risk. Plenty of sound stocks lose share value just because they get carried along by the general currents.

  • Dow Jones Futures Rise After 'Hard' Reality Hits Market; What To Do Now

    Dow Jones futures rose, but be wary after the stock market suffered another week of solid losses as fears grew of a "hard" economic landing.

  • How Low Could the S&P 500 Sink? According to History, 3000.

    History indicates that several more months of pain are in store for the bulls, whose best hope might be that the benchmark index doesn’t slip below 3600, 7.7% under this past week’s close.

  • Nasdaq Sell-Off: 2 Growth Stocks Billionaires Were Buying in Q1

    The Nasdaq Composite fell 9% in the first quarter, as many investors weighed concerns about the strength of the economy. Likewise, billionaire James Simons of Renaissance Technologies doubled down on Tesla (NASDAQ: TSLA), and the stock now ranks as the second-largest holding in his hedge fund.

  • Want to Get Richer? 5 Top Stocks to Buy Now and Hold Forever

    You've heard the expression that "a diamond is forever." Here are the "diamonds" of tech.

  • Broadcom in talks to acquire VMware -sources

    (Reuters) -Chipmaker Broadcom Inc is in talks to acquire cloud service provider VMware Inc, people familiar with the matter told Reuters. Negotiations between Broadcom and VMware are ongoing and a deal is not imminent, the sources said. The acquisition would further diversify Broadcom’s business away from semiconductors and into enterprise software, following its $18.9 billion acquisition of CA Technologies and its $10.7 billion purchase of Symantec Corp’s security division in the last four years.

  • Amazon Aims to Sublet, End Warehouse Leases as Online Sales Cool

    (Bloomberg) -- Amazon.com Inc., stuck with too much warehouse capacity now that the surge in pandemic-era shopping has faded, is looking to sublet at least 10 million square feet of space and could vacate even more by ending leases with landlords, according to people familiar with the situation. Most Read from BloombergWalmart’s Troubles Should Have Everyone on High AlertA $5 Trillion ‘Wealth Shock’ Is Cracking Americans’ Nest EggsBroadcom in Talks to Acquire Cloud Company VMwareHow an Energy Ex